298 related articles for article (PubMed ID: 36173644)
1. A comprehensive review of pancreatic cancer and its therapeutic challenges.
Jiang S; Fagman JB; Ma Y; Liu J; Vihav C; Engstrom C; Liu B; Chen C
Aging (Albany NY); 2022 Sep; 14(18):7635-7649. PubMed ID: 36173644
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine.
Ayasun R; Saridogan T; Gaber O; Sahin IH
Clin Colorectal Cancer; 2023 Mar; 22(1):2-11. PubMed ID: 36418197
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
6. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA; Görgülü K; Wörmann SM; Algül H
Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
[TBL] [Abstract][Full Text] [Related]
9. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.
Xu ZH; Wang WQ; Liu L; Lou WH
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188751. PubMed ID: 35732240
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
11. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.
Coppola S; Carnevale I; Danen EHJ; Peters GJ; Schmidt T; Assaraf YG; Giovannetti E
Drug Resist Updat; 2017 Mar; 31():43-51. PubMed ID: 28867243
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA H19, a novel therapeutic target for pancreatic cancer.
Wang J; Zhao L; Shang K; Liu F; Che J; Li H; Cao B
Mol Med; 2020 Apr; 26(1):30. PubMed ID: 32272875
[TBL] [Abstract][Full Text] [Related]
14. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
16. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
17. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.
Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H
Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345
[TBL] [Abstract][Full Text] [Related]
18. The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.
Hawa Z; Haque I; Ghosh A; Banerjee S; Harris L; Banerjee SK
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240340
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
[TBL] [Abstract][Full Text] [Related]
20. Mouse Models of Pancreatic Ductal Adenocarcinoma.
Ponz-Sarvise M; Tuveson DA; Yu KH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]